East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Adalimumab
Adalimumab
Routinely available
SMC (1050/15)
04/12/2024

Indication

For the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy.

For the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy.

Therapeutic Area

Musculoskeletal and joint diseases

Status Description

Routinely available in line with national guidance

Formulation

-

Comments

Refer to pathway or local board guidelines for preferred formulation

Link to Advice

1050/15

Advice Published

11/05/2015

SMC Submission Type

Abbreviated

SMC Status

Restricted